Sumitomo Pharma And Otsuka Announce Topline Results From Phase 3 Diamond1 And Diamond2 Clinical Studies Evaluating Ulotaront In Schizophrenia
31/07/2023 05:12
July 31 (Reuters) - Sumitomo Pharma Co Ltd 4506.T :
* SUMITOMO PHARMA CO LTD - SUMITOMO PHARMA AND OTSUKA
ANNOUNCE
TOPLINE RESULTS FROM PHASE 3 DIAMOND1 AND DIAMOND2 CLINICAL
STUDIES EVALUATING ULOTARONT IN SCHIZOPHRENIA
Source text for Eikon: ID:nTSsd81479
Further company coverage: 4506.T
Recent news on Otsuka Holdings
See all newsOtsuka, Ionis' experimental ALS drug meets main goal in late-stage study
Brief: Otsuka Pharmaceutical Announces Ulefnersen Early Access Program For Eligible People Living With FUS-ALS
Brief: Otsuka Pharmaceutical Says Phase 3 Fusion Results For Ulefnersen Met Primary Endpoint
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit In Rezilient3 Phase 3 Trial In First-Line Egfr Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Climb Bio rises after early-stage data for kidney disease drug